Veracyte | VCYT - Equity Capital And Reserves


Veracyte reported $1.26B in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
Agenus USD -274.14M 80.46M Sep/2025
Agilent USD 6.91B 167M Dec/2025
Anika Therapeutics USD 146.8M 867K Sep/2025
Arrowhead Research USD 568.42M 102.37M Dec/2025
Bruker USD 2.49B 625.6M Sep/2025
Exact Sciences USD 2.4B 100.37M Dec/2025
Heron Therapeutics USD 14.88M 42.14M Sep/2025
Illumina USD 2.72B 342M Dec/2025
Intrexon USD 43.17M 75.33M Jun/2024
Karyopharm Therapeutics USD -269.26M 30.33M Sep/2025
Laboratory Of America USD 8.62B 93.2M Dec/2025
Ligand Pharmaceuticals USD 950.17M 121.64M Sep/2025
Myriad Genetics USD 372.8M 15.3M Sep/2025
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Roche Holding CHF 33.8B 758M Dec/2025
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Siemens EUR 65.48B 3.24B Dec/2025
Sonic Healthcare AUD 8.2B 120.9M Dec/2024
Thermo Fisher Scientific USD 53.54B 2.38B Dec/2025
Veracyte USD 1.26B 36.61M Sep/2025
Waters USD 2.56B 230.55M Dec/2025